“…Behavioral outcomes are a key functional measure of underlying improvements in molecular and cellular function, which often impact central regulatory pathways. Previously, ISRIB has been shown to improve cognitive function in brain injury (Chang et al, 2021; Chou et al, 2017), cancer (Lorenz et al, 2021), neuropsychiatric disorders (Kabir et al, 2017), neurodegenerative disorders (Oliveira et al, 2021; Wong et al, 2018; Xu et al, 2021), and even healthy cognition (Sidrauski et al, 2013). Our study demonstrated the beneficial effects of ISRIB in a mouse model of FXS, which in combination with recent studies showing the impact of ISRIB treatment in models of Down syndrome (Zhu et al, 2019) and MEHMO (Mental retardation, Epileptic seizures, Hypogonadism and Hypogenitalism, Microcephaly, and Obesity), a rare X-linked disorder (Young-Baird et al, 2020), expands its therapeutic potential to neurodevelopmental disorders.…”